Stay updated with breaking news from Gary Waanders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO ... | April 8, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Identification of ten novel tumor-specific antigens immunogenic for T cells Planegg/Martinsried and Montréal - 10 April 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents the screening and identification of novel immunogenic tumor-specific antigens (TSAs) derived from non-coding regions of the human genome at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2021. The poster can be found on Medigene's website: https://www.medigene.com/technologies/abst...
Medigene AG: Focus on solid tumors - Discontinuation of MDG1021 development program Conference call today, 3.00 pm CET (9.00 am ET) Planegg/Martinsried (pta025/28.01.2021/14:10) - 28 January 2021. The Executive Management of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, with approval of the Supervisory Board decided today that, consistent with the company's recent decision to focus its development efforts on solid tumors, the MDG1021 development program is to be discontinued. Recruitment for t...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare ... Medigene AGJanuary 5, 2021 GMT MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the Lif...